ATXS News and Press, Astria Therapeutics Inc. From 02/06/24

2024-02-06 12:46:00 ET More on Astria TherapeuticS Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout Astria Therapeutics stock jumps on pricing of $125M underwritten offering Astria TherapeuticS GAAP EPS of -$0.63 misses by $0.14 ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer...

2024-02-04 04:19:51 ET Summary Astria Therapeutics (formerly Catabasis Pharmaceuticals) acquired Quellis Biosciences and its lead program, STAR-0215, for the treatment of hereditary angioedema (HAE) in 2021. The company has successfully completed a Phase 1 study for STAR-0215, dem...

2024-01-30 10:09:22 ET More on Astria TherapeuticS Astria Therapeutics, Inc. (ATXS) Q3 2023 Earnings Call Transcript Astria Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Astria TherapeuticS GAAP EPS of -$0.63 misses by $0.14 Seeking Alpha&...

Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, tod...

2023-12-15 11:54:45 ET More on Astria TherapeuticS Astria TherapeuticS GAAP EPS of -$0.63 misses by $0.14 Astria Therapeutics prices $64 million securities offering For further details see: Astria Therapeutics files $500M mixed securities shelf

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share STAR-0215 Phase 1a results in an encore presentation at the annual World Allergy Congress on Sunday, Dec...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215 and STAR...

2023-11-13 08:01:42 ET More on Astria TherapeuticS Astria Therapeutics: Too Much Baggage, Too Strong A Competition Astria Therapeutics prices $64 million securities offering Astria signs licensing deal with Ichnos Sciences to develop atopic dermatitis treatment ...

-- New Phase 1a Results Confirm Potential for STAR-0215 to Prevent HAE Attacks with Dosing 2 or 4 Times Per Year -- -- ALPHA-STAR Trial of STAR-0215 Initial Proof-of-Concept Data in Patients Now Expected Q1 2024 -- -- STAR-0310, Potential Best-in-Class OX40 Program for the Treatme...